Pfizer Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.03B | $14.45B | $17.56B | $16.65B | $14.65B | $13.72B | $17.76B | $17.70B |
| Cost of Revenue | $4.09B | $3.55B | $5.27B | $4.17B | $3.78B | $2.85B | $5.91B | $5.26B |
| Gross Profit | $10.94B | $10.90B | $12.29B | $12.48B | $10.88B | $10.87B | $11.85B | $12.44B |
| Gross Margin | 72.8% | 75.4% | 70.0% | 74.9% | 74.2% | 79.3% | 66.7% | 70.3% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $3.41B | $2.96B | $4.16B | $3.19B | $3.42B | $3.03B | $4.27B | $3.24B |
| Operating Income | $14.0M | $3.84B | $-932.0M | $3.99B | $3.70B | $3.44B | $730.0M | $5.50B |
| Operating Margin | 0.1% | 26.6% | -5.3% | 23.9% | 25.2% | 25.1% | 4.1% | 31.1% |
| Interest Expense | $667.0M | $668.0M | $711.0M | $652.0M | $654.0M | $654.0M | $740.0M | $783.0M |
| Pretax Income | $-653.0M | $3.17B | $-1.64B | $3.33B | $3.04B | $2.79B | $-10.0M | $4.72B |
| Income Tax Expense | $-407.0M | $461.0M | $-2.0M | $-216.0M | $141.0M | $-189.0M | $-421.0M | $234.0M |
| Net Income | $-248.0M | $2.69B | $-1.65B | $3.54B | $2.91B | $2.97B | $410.0M | $4.47B |
| Net Margin | -1.6% | 18.6% | -9.4% | 21.3% | 19.9% | 21.6% | 2.3% | 25.2% |
| EPS (Basic) | $-0.04 | $0.47 | $-0.28 | $0.62 | $0.51 | $0.52 | $0.07 | $0.79 |
| EPS (Diluted) | $-0.04 | $0.47 | $-0.29 | $0.62 | $0.51 | $0.52 | $0.07 | $0.78 |
| Shares Outstanding (Basic) | 5.70B | 5.69B | 5.68B | 5.69B | 5.69B | 5.68B | 5.66B | 5.67B |
| Shares Outstanding (Diluted) | 5.70B | 5.73B | 5.71B | 5.71B | 5.71B | 5.71B | 5.70B | 5.71B |
| Dividends Per Share | $0.86 | $0.00 | $0.86 | $0.00 | $0.86 | $0.00 | $0.85 | $0.00 |